ImmunoPrecise Antibodies Ltd. engages in the antibody production and related services in the United States, Canada, and Europe. It also provides human antibody development, hybridoma development, genetic immunization, rabbit monoclonal antibody development, recombinant protein expression and production, cryostorage, hybridoma sequencing, antibody generation, antibody purification, polyclonal development, and peptide production services. The company has a collaboration agreement with TetraGenetics, Inc. The company was founded in 1989 and is based in Victoria, Canada.
Industry, Sector and Symbol
Industry Biotechnology
Sub-IndustryN/A
SectorMedical
CIKN/A
Phone+1-604-8060626
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesC$10.77 million
Profitability
Miscellaneous
EmployeesN/A
Next Earnings DateN/A
OptionableNot Optionable
Immunoprecise Antibodies (CVE:IPA) Frequently Asked Questions
What is Immunoprecise Antibodies' stock symbol?
Immunoprecise Antibodies trades on the Canadian Venture Exchange (CVE) under the ticker symbol "IPA."
Has Immunoprecise Antibodies been receiving favorable news coverage?
Press coverage about IPA stock has trended somewhat negative on Monday, InfoTrie Sentiment Analysis reports. InfoTrie ranks the sentiment of news coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Immunoprecise Antibodies earned a media sentiment score of -1.7 on InfoTrie's scale. They also assigned news coverage about the company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an effect on the stock's share price in the immediate future. View News Stories for Immunoprecise Antibodies.
Who are some of Immunoprecise Antibodies' key competitors?
Some companies that are related to Immunoprecise Antibodies include Ampliphi Biosciences (APHB), Verseon (VSN), 22nd Century Group (XXII), Antibe Therapeutics (ATE), Cynata Therapeutics (CYP), OncoCyte (OCX), OncoCyte (OCX), MediGene (MDG1), Faron Pharmaceuticals Oy (FARN), Novoheart (NVH), Lineage Cell Therapeutics (LCTX), BioTime (BTX), Imugene (IMU), Oxford Biodynamics (OBD) and Burcon NutraScience (BU).
What other stocks do shareholders of Immunoprecise Antibodies own?
Who are Immunoprecise Antibodies' key executives?
Immunoprecise Antibodies' management team includes the folowing people:
- Dr. James S. Kuo M.B.A., M.D., Chairman (Age 54)
- Dr. Jennifer Bath, Pres, CEO & Director
- Mr. Robert Beecroft, Founder & Director
- Mr. Charles Wheelock, Global Chief Technology Officer
- Ms. Lisa Helbling, Chief Financial Officer
How do I buy shares of Immunoprecise Antibodies?
Shares of IPA and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade and Charles Schwab.
What is Immunoprecise Antibodies' stock price today?
One share of IPA stock can currently be purchased for approximately C$0.51.
How big of a company is Immunoprecise Antibodies?
What is Immunoprecise Antibodies' official website?
How can I contact Immunoprecise Antibodies?
Immunoprecise Antibodies' mailing address is 880-580 Hornby St, VANCOUVER, BC V6C 3B6, Canada. The company can be reached via phone at +1-604-8060626.
MarketBeat Community Rating for Immunoprecise Antibodies (CVE IPA)
MarketBeat's community ratings are surveys of what our community members think about Immunoprecise Antibodies and other stocks. Vote "Outperform" if you believe IPA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe IPA will underperform the S&P 500 over the long term. You may vote once every thirty days.
